Document:

<PAGE>

                                                                    EXHIBIT 10.6

                              EMPLOYMENT AGREEMENT

     This AGREEMENT, dated August 13, 2001, is between ZymoGenetics, Inc., a
                           ---------
Washington corporation ("Company") and Shinko U. Campos ("Executive").
                         -------                          ----------

     1.  Employment. Company will employ Executive and Executive will accept
         ----------
employment as Sr. Vice President, Operations, of the Company.  Executive accepts
employment upon the terms and conditions contained in this Agreement and for the
period (hereinafter called the "Term of Employment") specified in Section 3
                                ------------------
below.

     2.  Duties. Executive shall, during the Term of Employment, serve the
         ------
Company under the direction of the President of the Company.  Executive shall
perform the duties of her position faithfully, diligently and competently and to
the best of her ability, and shall devote her full business time to her
employment. Executive shall perform such other duties as are assigned to her by
the President or the Board of Directors of the Company.  Executive shall not
engage in any other business activity (except the management of personal
investments which in the aggregate do not interfere with the performance of
Executive's duties) without first obtaining the written consent of Company, such
consent not to be unreasonably withheld.

     3.  Term of Employment; Termination.
         -------------------------------

     Executive's Term of Employment shall be two years from the date of this
Agreement, unless extended or earlier terminated as provided below.

     (a) Termination or Extension of Term of Employment By Company

     The Company shall employ Executive, for a period commencing on the date
hereof and terminating as follows:

          (i) Two years from the date hereof, if at least thirty (30) days prior
to such date either the Company or Executive has, at its election, notified the
other in writing that this Agreement shall terminate on such date.  If notice of
termination is not given, this Agreement shall be deemed to extend from year to
year.  It can then be terminated by written notice at least thirty (30) days
prior to the annual renewal date.

          (ii) With or without "Cause" (as defined below), Company may terminate
the employment of Executive at any time upon giving "Notice of Termination" (as
defined below).
<PAGE>

     (b)  By Executive

     Executive may terminate her employment at any time, for any reason, upon
giving Notice of Termination.

     (c)  Automatic Termination

     This Agreement and Executive's employment hereunder shall terminate
automatically upon the death or total disability of Executive.  The term "total
                                                                          -----
disability" as used herein shall mean Executive's inability to perform the
----------
duties set forth in paragraph 1 hereof for a period or periods aggregating
ninety (90) calendar days in any 12-month period as a result of physical or
mental illness, loss of legal capacity or any other cause beyond Executive's
control, unless Executive is granted a leave of absence by the Board of
Directors of Company.  Executive and Company hereby acknowledge that Executive's
ability to perform the duties specified in paragraph 2 hereof is of the essence
of this Agreement.  Termination hereunder shall be deemed to be effective (a) at
the end of the calendar month in which Executive's death occurs or (b)
immediately upon a determination by the Board of Directors of Company of
Executive's total disability, as defined herein.

     (d)  Notice

     The term "Notice of Termination" shall mean at least thirty (30) days'
               ---------------------
written notice of termination, by either party, of Executive's employment,
during which period Executive's employment and performance of services will
continue; provided, however, that Company may, upon notice to Executive and
without reducing Executive's compensation during such period, excuse Executive
from any or all of her duties during such period.  Such a reduction in duties
shall not constitute "good reason" for voluntary termination so as to trigger
termination payments in accordance with subparagraph 4.2.  The effective date of
the termination (the "Termination Date") of Executive's employment hereunder
                      ----------------
shall be the date on which such 30-day period expires.

     4.  Termination Payments
         --------------------

     In the event of termination of the employment of Executive, all
compensation and benefits set forth in this Agreement shall terminate except as
specifically provided in this paragraph 4:

                                      -2-
<PAGE>

     4.1  Termination by Company

     (a)  Upon termination by Company, Company shall pay Executive any unpaid
annual base salary which has accrued for services already performed as of the
Termination Date.

     (b)  If Company terminates Executive's employment without Cause, as defined
below, Executive shall be entitled to receive termination payments equal to
twelve (12) months annual base salary.  The termination payments shall be
calculated according to Executive's base salary as of the date of Notice of
Termination and the termination payments will be paid semi-monthly in equal
parts in accordance with the same time schedule that Company or a "Successor
                                                                   ---------
Company" (as defined in the Stock Option Agreement and incorporated by reference
-------
herein) makes its customary payroll.  Company or a Successor Company may deduct
customary withholdings including social security, federal and state income
taxes, and state disability insurance from these severance payments; however,
any and all such obligations shall be Executive's responsibility.  Company will
issue and file appropriate Form 1099 or similar tax documents in connection with
any termination payments.  The termination payments described in this paragraph
are expressly contingent upon Executive's full compliance with the terms of her
Employee Inventions and Proprietary Information Agreement with Company (the
"Inventions Agreement"), a copy of which is attached hereto.  In the event
---------------------
Executive were to materially breach this Inventions Agreement, her right to any
termination payments under this paragraph shall be extinguished, Company (and
any Successor Company) shall cease payments, and Executive shall immediately
return to Company or to any Successor Company any severance payments already
made.  If Executive is terminated by either Company or any Successor Company for
Cause, Executive shall not be entitled to receive any of the foregoing benefits,
other than those set forth in clause (a) above.

     4.2  Termination by Executive

     In the case of the termination of Executive's employment by Executive for
"good reason," as defined below, Executive shall be entitled to the termination
payments as set forth in clauses 4.1(a) and (b).  In the case of termination of
Executive's employment by Executive for any other reason, Executive shall not be
entitled to any termination payments or accelerated vesting benefit, other than
as set forth in clause 4.1(a), above.

                                      -3-
<PAGE>

     4.3  Termination as a Result of Death or Total Disability

     In the event of termination of Executive's employment pursuant to
subparagraph 3(c), Executive or her estate shall be paid the compensation set
forth in clause 4.1(a) and shall not be entitled to any of the benefits under
clauses 4.1(b).

     4.4  "Good Reason"

     "Good reason" shall mean the occurrence of any of the following events,
      -----------
without the consent of the Executive:

      a)  a demotion or other material reduction in the nature or status of
          Executive's responsibilities; provided, however, that a change in the
          person or office to which Executive reports, without a corresponding
          reduction in duties, status and and responsibilities, shall not
          constitute "good reason;"

      b)  a non-voluntary reduction in the Executive's annual base salary;

      c)  requirement by a Successor Company that the Executive relocate her
          principal place of employment to a location that is more than 50 miles
          from the principal place of employment where Executive was employed;
          or

      d)  the failure of Company to obtain a satisfactory agreement from any
          Successor Company to assume and perform the obligations under this
          Agreement.

     4.5  Cause

     Wherever reference is made in this Agreement to termination being with or
without Cause, "Cause" shall include, without limitation, the occurrence of one
                ------
or more of the following events:

      a)  willful misconduct, insubordination, or dishonesty in the performance
          of Executive's duties or other knowing and material violation of
          Company's or a Successor Company's policies and procedures in effect
          from time to time which results in a material adverse effect on
          Company or a Successor Company;

      b)  willful actions (or intentional failures to act) in bad faith by
          Executive with respect to Company or a Successor Company that
          materially impair Company's or a Successor Company's business,
          goodwill or reputation;

                                      -4-
<PAGE>

      c)  conviction of Executive of a felony involving an act of dishonesty,
          moral turpitude, deceit or fraud, or the commission of acts that could
          reasonably be expected to result in such a conviction; or

      d)  any material violation by Executive of Executive's Inventions
          Agreement with Company.

     5.  Compensation and Fringe Benefits.
         --------------------------------

     (a)  The Company shall, during the Term of Employment, pay to the Executive
as compensation for the performance of her duties and obligations a salary of
$220,928 per annum.  This compensation is subject to annual review and
adjustment, as appropriate in the judgment of the Company.  The compensation
payable pursuant to this Section 5(a) shall be payable in equal semi-monthly
installments on the last day of each such pay period.

     (b)  The Executive shall be enrolled and participate in any retirement,
group insurance and other fringe benefit plans and arrangements which are
applicable to the similarly situated personnel of the Company and in effect from
time to time, if the Executive is eligible therefor, in each case in accordance
with and subject to the provisions thereof.

     (c)  Stock Options

          (i)    Executive has been granted a ten-year stock option under the
Company's Amended and Restated 2000 Stock Incentive Plan, dated August 23, 2000,
which allows Executive to purchase 50,000 shares of the Company's common stock.

          (ii)   Executive shall be eligible to receive future grants of stock
options pursuant to the Company's stock-based bonus program; and

          (iii)  Executive shall be eligible to receive future periodic (i.e.,
non bonus-related) grants under the Company's stock incentive programs.

     (d) Executive will also receive the following executive perquisites for the
duration of this contract:

          (i)    Company-paid term life insurance policy in the amount of
$200,000; and

          (ii)   Company-paid use of either a laptop computer or personal
computer, to be upgraded bi-annually at the time this contract is renewed; and

                                      -5-
<PAGE>

          (iii)  Company-paid annual executive health physical, to be
administered by a physician selected by the Company; and

          (iv)   Company-paid expenses for a residential phone and cellular
phone.

     6.   Expenses.  All travel and other reasonable expenses incident to the
          --------
rendering of service by the Executive hereunder will be paid by the Company.  If
such expenses are paid in the first instance by the Executive, the Company will
reimburse him upon presentation of proper expense accounts.  Reimbursement
requests, along with supporting documentation, should be submitted within sixty
(60) days of incurring the expense.

     7.   Non-competition.
          ---------------

    (a) Upon termination of Executive's employment with the Company for any
reason, and for a period of twelve (12) consecutive months after leaving her
employment with the Company, Executive will not directly or indirectly work or
otherwise engage in research, manufacture, sale or distribution of any product,
method or matter:

          (i)  For any business, whose commercial efforts are in competition
with the products manufactured or marketed by the Company during Executive's
employment with the Company or under research or development by the Company
during Executive's employment with the Company (and on which the Company has
expended at least $500,000); or

          (ii) For any research institution whose research efforts pertain to
the same products manufactured or marketed by the Company during Executive's
employment with the Company or under research or development by the Company
during Executive's employment with the Company (and on which the Company has
expended at least $500,000), unless the Executive is not involved in any manner
in the design, conduct or supervision of such research efforts, or unless such
research is being conducted solely for scientific and not for commercial
purposes.  The executive shall be deemed to be connected with a business if such
business is carried on by partnership in which she is a general or limited
partner, consultant or employee, or a corporation or association of which she is
a shareholder, officer, director, employee, member, consultant or agent;
provided, that nothing herein shall prevent the purchase or ownership by the
Executive of shares of less than 1% of the outstanding shares in a publicly or
privately held corporation.

                                      -6-
<PAGE>

     Said twelve (12) months' period shall commence on the day on which the
Executive actually leaves her employment with the Company, even if this date is
prior to the expiration of any given notice of termination.

     (b) The Company's Board of Directors may, at its own discretion, by express
or written consent, release the Executive from the restriction in paragraph
6(a).

     (c) For a period of one (1) year after the employment of the Executive is
terminated for any reason, Executive will not directly or indirectly, either for
Executive's account or as representative or agent for any other person, firm,
corporation or entity, solicit the services of, or entice away, any Executive of
the Company, or the Executive of any company affiliated with the Company.

     (d) In the event that Executive during said period described in paragraph
6(a) violates any of the Executive's obligations towards the Company, including
but not limited to the Executive accepting a position with a competing
enterprise or Executive violating terms of paragraph 6(c), payment of Severance
or Salary Continuation shall cease automatically without notice, regardless of
whether the Company takes legal action or otherwise tries to enforce its rights.
The Company reserves all rights it may have under contract or law to relief or
damages in addition to termination of the above-described payments.

     8.  Binding Effect.  This Agreement shall be binding upon and inure to the
         --------------
benefit of the Company and the Executive and their respective heirs, legal or
personal representatives, successors and assigns.

     9.  Rights of Assignment or Delegation.  This Agreement is personal to the
         ----------------------------------
Executive and shall not be assignable.  Company may assign its rights hereunder
to (a) any corporation resulting from any merger, consolidation, or other
reorganization to which Company is a party or (b) any corporation, partnership,
association, or other person to which Company may transfer all or substantially
all of the assets in business of Company existing at such time.  All the terms
and provisions of this Agreement shall be binding upon and shall inure to the
benefit and be enforceable by the parties hereto and their respective successors
and permitted assigns.

     10. Waiver.  No delay or failure by any party in exercising, protecting or
         ------
enforcing any of its rights, titles, interests, or remedies hereunder and no
course of dealing or performance with respect thereto, shall constitute a
waiver.  The express waiver by a party of any right, title, interest, or remedy
in a particular instance or circumstance shall not constitute a waiver in any
other instance or circumstance.  All rights and remedies shall be cumulative and
not exclusive or any rights or remedies.

                                      -7-
<PAGE>

     11.  Arbitration.  Any controversies or claims arising out of or relating
          -----------
to this Agreement shall be finally and fully settled by arbitration of the City
of Seattle, Washington in accordance with the Employment Arbitration Rules of
the American Arbitration Association then in effect (the "AAA Rules"), conducted
by one arbitrator, mutually agreed upon by Company and Executive or chosen in
accordance with the AAA Rules, except the parties thereto shall have any right
to discovery would be permitted by the Federal Rules of Civil Procedure for a
period of 90 days following the commencement of such arbitration and the
arbitrator shall resolve any dispute which arises in connection with such
discovery.  The prevailing parties shall be entitled to costs, expenses,
reasonable attorneys' fees, and judgment upon the award rendered by the
arbitrator.  The award may be entered in any court having jurisdiction.

     12.  Amendments in Writing.  No amendment, modification, waiver,
          ---------------------
termination or discharge of any provision of this Agreement, nor consent to any
departure by either party, shall in any event be effective unless the same shall
be in writing, specifically identifying this Agreement and the provision
intended to be amended, modified, waived, terminated, or discharged and assigned
by Company and Executive.  Each such amendment, modification, waiver,
termination, or discharge shall be effective only in the specific instance and
for the specific purpose for which given.  No provision of this Agreement shall
be varied, contradicted, or explained by any oral agreement, course of dealing
or performance or any other matter not set forth in agreement in writing and
signed by Company and Executive.

     13.  Notices.  Any notice required or desired to be given hereunder shall
          -------
be in writing and shall be deemed sufficiently given when delivered or when
mailed by first class certified or registered mail, postage prepaid, to the
party for whom intended at the following address:

     To the Company:

               Dr. Bruce L.A. Carter
               CEO and President
               ZymoGenetics, Inc.
               1201 Eastlake Avenue East
               Seattle, WA 98102

     To the Executive:

               Shinko U. Campos
               Sr. Vice President, Operations
               24180 - 116th West
               Edmonds, WA 98020

                                      -8-
<PAGE>

or to such other address, as to either party, as such party shall from time to
time designate by like notice to the other.

     14.  Entire Agreement.  This Agreement will, upon the commencement of the
          ----------------
Term of Employment, supersede all prior agreements between the Executive and the
Company, except the Employee Inventions and Proprietary Information Agreement
dated April 8, 1998, and any such prior agreements and the terms and conditions
thereof shall hereafter be null, void and of no effect.

     15.  Governing Law.  This Agreement is made under and shall be governed by
          -------------
and construed in accordance with the internal laws of the State of Washington.

     16.  Severability.  If any provision of this Agreement shall be held
          ------------
invalid, illegal or unenforceable in any jurisdiction, for any reason, including
without limitation, the duration of such provision, it's geographical scope or
the extent of the activities prohibited or required by it, then, to the full
extent permitted by law (a) all other provisions hereof shall remain in full
force and effect and such jurisdiction shall be liberally construed in order to
carry out the intent of the parties as nearly as may be possible, (b) such
invalidity, illegality, or unenforcability shall not effect the validity,
legality or enforceability of any other provision, and (c) any court or
arbitrator having jurisdiction there over shall have the power to reform such
provision to the extent necessary for such provision to be enforceable under
applicable law.

     17.  Multiple Copies.  This Agreement may be executed in two or more
          ---------------
counterparts of like tenor and effect, each of which shall be deemed an original
but all of which together shall constitute one and the same instrument.

                              ZYMOGENETICS, INC.

                              By: /s/ Bruce L.A. Carter
                                 -------------------------------------
                              Dr. Bruce L.A. Carter, President and CEO

                              EXECUTIVE:

                              /s/ Shinko U. Campos
                              ----------------------------------------
                              Shinko U. Campos

                                      -9-<PAGE>

                                                                    EXHIBIT 10.7

                              ZYMOGENETICS, INC.

                  SERIES B PREFERRED STOCK PURCHASE AGREEMENT

                               October 20, 2000
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
         <S>                                                                                             <C>
         1.       Purchase and Sale of Stock............................................................  1

                  1.1      Sale and Issuance of Series B Preferred Stock................................  1

                  1.2      Closing......................................................................  2

         2.       Representations and Warranties of the Company.........................................  2

                  2.1      Organization, Valid Existence and Qualification..............................  2

                  2.2      Capitalization...............................................................  2

                  2.3      Subsidiaries.................................................................  3

                  2.4      Authorization................................................................  4

                  2.5      Valid Issuance of Preferred and Common Stock.................................  4

                  2.8      Litigation...................................................................  6

                  2.9      Intellectual Property........................................................  6

                  2.10     Restructuring Agreements.....................................................  8

                  2.11     Compliance with Other Instruments............................................  8

                  2.12     Agreements; Action...........................................................  9

                  2.13     Related-Party Transactions...................................................  9

                  2.14     Permits...................................................................... 10

                  2.15     Environmental Laws........................................................... 10

                  2.16     Registration Rights and Voting Rights........................................ 11

                  2.17     Title to Property and Assets................................................. 11

                  2.18     Employee Benefit Plans....................................................... 12

                  2.19     Tax Returns, Payments and Elections.......................................... 13

                  2.20     Employment and Labor Matters................................................. 13
</TABLE>

                                      -i-
<PAGE>

<TABLE>
         <S>                                                                                              <C>
                  2.21     Brokers......................................................................  14

                  2.22     Absence of Certain Developments..............................................  14

                  2.23     Illegal or Unauthorized Payments; Political Contributions....................  15

                  2.24     Insurance....................................................................  15

                  2.25     Full Disclosure..............................................................  15

                  2.26     Minute Books.................................................................  15

                  2.27     Knowledge....................................................................  16

         2A.      Representations and Warranties of Novo Nordisk........................................  16

                  2A.1     Restructuring Agreements.....................................................  16

                  2A.2     Intellectual Property........................................................  16

         3.       Representations and Warranties of the Investors.......................................  16

                  3.1      Authorization................................................................  16

                  3.2      Purchase Entirely for Own Account............................................  17

                  3.3      Disclosure of Information....................................................  17

                  3.4      Investment Experience........................................................  17

                  3.5      Accredited Investor..........................................................  18

                  3.6      Restricted Securities........................................................  18

                  3.7      Further Limitations on Disposition...........................................  18

                  3.8      Legends......................................................................  19

                  3.9      No Public Market.............................................................  19

         4.       Conditions of Investors' Obligations at Closing.......................................  19

                  4.1      Representations and Warranties...............................................  19

                  4.2      Performance..................................................................  20
</TABLE>

                                      -ii-
<PAGE>

<TABLE>
         <S>                                                                                              <C>
                  4.3      Compliance Certificate.......................................................  20

                  4.4      Restated Articles; Secretary's Certificate...................................  20

                  4.5      Qualifications...............................................................  20

                  4.6      Rights Agreement.............................................................  20

                  4.7      Co-Sale Agreement............................................................  20

                  4.8      Shareholders' Agreement......................................................  20

                  4.9      Restructuring Agreements.....................................................  21

                  4.10     Executive Employment Agreement...............................................  21

                  4.11     Opinion of Company Counsel...................................................  21

                  4.12     Proceedings and Documents....................................................  21

         5.       Conditions of the Company's Obligations at Closing....................................  21

                  5.1      Representations and Warranties...............................................  21

                  5.2      Payment of Purchase Price....................................................  21

                  5.3      Qualifications...............................................................  21

                  5.4      Rights Agreement.............................................................  22

                  5.5      Co-Sale Agreement............................................................  22

                  5.6      Shareholders' Agreement......................................................  22

         6.       Covenants Pending Closing.............................................................  22

         7.       Miscellaneous.........................................................................  23

                  7.1      Survival of Warranties.......................................................  23

                  7.2      Successors and Assigns.......................................................  23

                  7.3      Governing Law; Jurisdiction; Venue...........................................  23

                  7.4      Counterparts.................................................................  23
</TABLE>

                                     -iii-
<PAGE>

<TABLE>
         <S>                                                                                              <C>
                  7.5      Titles and Subtitles.........................................................  23

                  7.6      Notices......................................................................  24

                  7.7      Finder's Fee.................................................................  24

                  7.8      Fees and Expenses............................................................  24

                  7.9      Amendments and Waivers.......................................................  24

                  7.10     Severability.................................................................  25

                  7.11     Entire Agreement.............................................................  25

                  7.12     Exculpation Among Investors..................................................  25

         EXHIBIT A         Schedule of Investors

         EXHIBIT B         Form of Amended and Restated Articles of Incorporation

         EXHIBIT C         Form of Investors' Rights Agreement

         EXHIBIT D         Form of Series B Co-Sale Agreement

         EXHIBIT E         Form of Shareholders' Agreement

         EXHIBIT F         Schedule of Exceptions

         EXHIBIT G         Form of Opinion of Perkins Coie LLP
</TABLE>

                                      -iv-
<PAGE>

                  SERIES B PREFERRED STOCK PURCHASE AGREEMENT

         This SERIES B PREFERRED STOCK PURCHASE AGREEMENT ("Agreement") is made
as of the 20th day of October, 2000, by and among ZymoGenetics, Inc., a
Washington corporation (the "Company"), Novo Nordisk A/S, a Danish company
("Novo Nordisk"), Warburg, Pincus Equity Partners, L.P., Warburg, Pincus
Netherlands Equity Partners I, C.V., Warburg, Pincus Netherlands Equity Partners
II, C.V. and Warburg, Pincus Netherlands Equity Partners III, C.V.
(collectively, "WPEP"), and the other investors listed on Exhibit A hereto
                                                          ---------
(collectively with WPEP, the "Investors", and individually, an "Investor").

                             W I T N E S S E T H:

         WHEREAS, the Investors desire to purchase and the Company desires to
sell and issue shares of the Series B Convertible Preferred Stock of the
Company; and

         WHEREAS, on the date hereof the Company is a wholly-owned indirect
subsidiary of Novo Nordisk;

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants herein contained, and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged;

         THE PARTIES HEREBY AGREE AS FOLLOWS:

1.       Purchase and Sale of Stock

         1.1      Sale and Issuance of Series B Preferred Stock

                  (a) The Company shall adopt and file with the Secretary of
State of the State of Washington on or before the Closing (as that term is
defined in Section 1.2 below) the Amended and Restated Articles of Incorporation
in the form attached hereto as Exhibit B (the "Restated Articles").
                               ---------

                  (b) On or prior to the Closing, the Company shall have
authorized (i) the sale and issuance to the Investors of 4,011,768 shares Series
B Convertible Preferred Stock ("Series B Shares") and (ii) the issuance of the
shares of Voting Common Stock to be issued upon conversion of the Series B
Shares (the "Conversion Shares"). The Series B Shares and the Conversion Shares
shall have the rights, preferences, privileges and restrictions set forth in the
Restated Articles.

                  (c) Subject to the terms and conditions of this Agreement,
each Investor agrees, severally and not jointly, to purchase, and the Company
agrees to sell
<PAGE>

and issue to each Investor, that number of Series B Shares set forth opposite
such Investor's name on Exhibit A hereto for the purchase price set forth
thereon.

         1.2   Closing

         The purchase and sale of 4,011,768 Series B Shares shall take place at
the offices of Perkins Coie LLP, 1201 Third Avenue, 48/th/ Floor, Seattle,
Washington, at 2:00 p.m. on the third business day following the satisfaction or
waiver of the conditions set forth in Sections 4 and 5 hereto or at such later
time and place as the Company and WPEP mutually agree upon orally or in writing
(which time and place are designated as the "Closing"). At the Closing the
Company shall deliver to each Investor a certificate representing the Series B
Shares that such Investor is purchasing against payment of the purchase price
therefor by cashier's check or wire transfer.

2.       Representations and Warranties of the Company

         The Company hereby represents and warrants to each Investor that,
except as set forth on a Schedule of Exceptions attached hereto as Exhibit F
                                                                   ---------
(the "Schedule of Exceptions"), which exceptions shall be deemed to be
representations and warranties as if made hereunder:

         2.1   Organization, Valid Existence and Qualification

         The Company is a corporation duly organized and validly existing under
the laws of the State of Washington and has all requisite corporate power and
authority to carry on its business as now conducted and as proposed to be
conducted as described in the Private Placement Memorandum of the Company dated
June 2000 (the "Proposed Business"). The Company is duly qualified to transact
business and is in good standing as a foreign corporation in each jurisdiction
where the character of the properties owned, leased or operated by it or the
nature of its activities makes such qualification necessary, except where the
failure to be so qualified would not have a material adverse effect on the
Company, its financial condition, its business as presently conducted, the
Proposed Business or any of its properties or material assets ("Material Adverse
Effect").

         2.2   Capitalization

               (a)  The authorized capital stock consists or will consist, upon
the filing of the Restated Articles, of (i) One Hundred Million (100,000,000)
shares of Voting Common Stock (the "Voting Common Stock") 3,275,700 shares of
which are, or, upon the filing of the Restated Articles, will be issued and
outstanding, (ii) Thirty Million (30,000,000) shares of Non-Voting Common Stock
(the "Non-Voting Common Stock"), none of which are issued and outstanding, and
(iii) Thirty Million

                                      -2-
<PAGE>

(30,000,000) shares of Preferred Stock (the "Preferred Stock") 2,528,000 shares
of which are, or, upon filing of the Restated Articles, will be designated
Series A Convertible Preferred Stock ("Series A Shares"), all of which are , or,
upon filing of the Restated Articles, will be issued and outstanding, and
4,011,768 shares of which will be designated Series B Convertible Preferred
Stock, none of which are issued and outstanding. The outstanding shares of
capital stock of the Company have been duly authorized and validly issued and
are fully paid and non-assessable.

                  (b) The Company has or immediately prior to the Closing will
have reserved (i) 2,528,000 shares of Non-Voting Common Stock for issuance upon
conversion of the Series A Shares, (ii) 2,528,000 shares of Voting Common Stock
for issuance upon conversion of the shares of Non-Voting Common Stock issuable
upon conversion of the Series A Shares, (iii) 4,011,768 shares of Voting Common
Stock for issuance upon conversion of the Series B Shares.

                  (c) The Company has or immediately prior to the Closing will
have reserved 1,685,000 shares of Voting Common Stock for issuance to officers,
employees, consultants, agents, advisors and independent contractors of the
Company pursuant to the Company's Amended and Restated 2000 Stock Incentive Plan
(the "Plan") 1,172,200 of which are, as of the date of this Agreement, subject
to outstanding options, and 512,800 of which will be available for future
issuance.

                  (d) Except for (i) the conversion privileges of the Series A
Shares, the Series B Shares and the shares of Non-Voting Common Stock which may
be issued upon conversion of the Series A Shares; (ii) the right of first
refusal set forth in Section 2 of the Shareholders' Agreement; and (iii) options
to purchase up to 1,685,000 shares of Common Stock reserved for issuance
pursuant to the Plan; there are no options, warrants, conversion privileges or
other rights (or agreements for any such rights) outstanding to purchase or
otherwise obtain from the Company any of the Company's securities.

         2.3      Subsidiaries

         The Company does not presently own or control, directly or indirectly,
any interest in any other corporation, association, or other business entity.

         2.4      Authorization

                  (a) All corporate action has been taken on the part of the
Company, its officers, directors and shareholders necessary for the
authorization, execution and delivery of this Agreement, that certain Investors'
Rights Agreement in the form attached hereto as Exhibit C (the "Rights
                                                ---------
Agreement"), that certain Series B Co-Sale Agreement in the form attached hereto
as Exhibit D (the "Co-Sale Agreement"), that
   ---------

                                      -3-
<PAGE>

certain Shareholders' Agreement in the form attached as Exhibit E (the
                                                        ---------
"Shareholders' Agreement," and together with the Rights Agreement and the Co-
Sale Agreement, the "Related Agreements,") the performance of all obligations of
the Company hereunder and thereunder; and this Agreement constitutes the valid
and legally binding obligation of the Company, enforceable in accordance with
their respective terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, and other laws of general application
affecting enforcement of creditors' rights generally, and (ii) as limited by
laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies.

                  (b) All corporate action on the part of the Company, its
officers, directors and shareholders necessary for the authorization, issuance
(or reservation for issuance), sale and delivery of the Series B Shares being
sold hereunder and the Conversion Shares issuable upon conversion of the Series
B Shares will be taken prior to the Closing.

                  (c) Upon the execution and delivery thereof at the Closing,
the Related Agreements will constitute valid and legally binding obligations of
the Company, enforceable in accordance with their respective terms, except (i)
as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors' rights
generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, and (iii) to the
extent the indemnification provisions contained in the Rights Agreement may be
limited by applicable federal or state securities laws.

         2.5      Valid Issuance of Preferred and Common Stock

         The Series B Shares that are being purchased by the Investors
hereunder, when issued, sold and delivered in accordance with the terms of this
Agreement for the consideration expressed herein, will be duly and validly
issued, fully paid, and nonassessable, and will be free of restrictions on
transfer other than restrictions on transfer under this Agreement and the
Related Agreements and under applicable state and federal securities laws. The
Conversion Shares issuable upon conversion of the Series B Shares purchased
under this Agreement have been duly and validly reserved for issuance and, upon
issuance in accordance with the terms of the Restated Articles, will be duly and
validly issued, fully paid, and nonassessable and will be free of restrictions
on transfer other than restrictions on transfer under this Agreement and the
Related Agreements and under applicable state and federal securities laws.
Subject in part to the truth and accuracy of each Investor's representations set
forth in Section 3 of this Agreement, the offer, sale and issuance of the Series
B Shares as contemplated by this Agreement are exempt from the registration
requirements of applicable state and federal securities laws. The outstanding
shares of Common Stock and the

                                      -4-
<PAGE>

outstanding Series A Shares are all duly and validly authorized and issued,
fully paid and nonassessable, and were issued in accordance with the
registration or qualification provisions of the Securities Act of 1933, as
amended (the "Securities Act") and any relevant state securities laws, or
pursuant to valid exemptions therefrom.

         2.6   Governmental Consents

         No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or
local governmental authority on the part of the Company is required in
connection the consummation of the transactions contemplated by this Agreement,
except for (i) the filing of the Restated Articles with the Secretary of State
of the State of Washington; (ii) the filing of notices of the sale of Series B
Shares pursuant to Regulation D promulgated under the Securities Act and
applicable state securities laws, which filings will be effected within 15 days
of the Closing and (iii) compliance with the requirements of the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

         2.7   Financial Statements

         The Company has delivered to the Investors (a) balance sheets and
statements of operations, shareholders' equity and cash flows of the Company at
and for the fiscal years ended December 31, 1997, 1998 and 1999 and accompanying
notes, audited by PriceWaterhouseCoopers LLP, independent auditors and certified
public accountants, and (b) unaudited balance sheets and unaudited statements of
operations and cash flows of the Company at and for the nine months ending
September 30, 2000. All the foregoing financial statements (including the notes
thereto) are referred to as the "Financial Statements" and the balance sheet of
the Company at September 30, 2000 is referred to as the "Balance Sheet". The
Financial Statements have been prepared in conformity with GAAP consistently
applied throughout the periods covered, except as may be indicated in the notes
thereto, and present fairly the financial position, results of operations and
changes in financial position of the Company at the dates and for the periods
indicated, subject, in the case of the unaudited financial statements, to normal
recurring period-end adjustments and except that the unaudited financial
statements may not contain all of the notes required by GAAP. The Company has no
liabilities or obligations of any nature (absolute, accrued or contingent) that
are not fully reflected or reserved against in the Balance Sheet, as prescribed
by GAAP, except (i) liabilities or obligations incurred since the date of the
Balance Sheet in the ordinary course of business and consistent with past
practice, and (ii) obligations under contracts made in the ordinary course of
business that would not be required to be reflected in financial statements
prepared in accordance with GAAP. The

                                      -5-
<PAGE>

Company maintains and will continue to maintain standard systems of accounting
established and administered in accordance with GAAP.

         2.8      Litigation

         There is no action, suit, proceeding or investigation pending or, to
the Company's knowledge, currently threatened against the Company that questions
the validity of this Agreement or the Related Agreements, or the right of the
Company to enter into such agreements, or to consummate the transactions
contemplated hereby or thereby, or that might have, either individually or in
the aggregate, a Material Adverse Effect, or result in any change in the current
equity ownership of the Company. The Company is not a party or subject to the
provisions of any order, writ, injunction, judgment or decree of any court or
government agency or instrumentality. There is no action, suit, proceeding or
investigation by the Company currently pending or that the Company intends to
initiate.

         2.9      Intellectual Property

                  (a) To the best of the Company's knowledge, the Company has
sufficient title to and ownership of or sufficient rights to use, license,
sublicense, transfer, sell and assign all patents, patent applications, trade
names, trademarks, trademark applications, trade dress, service marks,
copyrights and mask works and all applications, registrations, and renewals in
connection therewith, computer software, together with all data and
documentation relating thereto, trade secrets, information, proprietary rights
and processes ("Intellectual Property") necessary for its business as now
conducted or the Proposed Business, without any conflict with or infringement of
the rights of others. Except as disclosed in the Schedule of Exceptions, the
Company has not granted any options or licenses relating to its Intellectual
Property, is not a party to or bound by any options, licenses or agreements with
respect to its Intellectual Property and has not entered into any agreements of
any kind relating to the Intellectual Property of any other person or entity, in
each case other than those options, licenses or other agreements which are not
material to the business of the Company as conducted or the Proposed Business.

                  (b) The Schedule of Exceptions contains a complete list of
patents, registered copyrights, registered trademarks and pending applications
therefor owned by the Company, together with a complete list of such types of
Intellectual Property under license to the Company. The Company has taken all
reasonable action to maintain and protect each item of Intellectual Property
owned by the Company and material to its business as conducted or the Proposed
Business. To the best of the Company's knowledge, each patent or patent
application owned by the Company and material to the business of the Company as
conducted or the Proposed Business is

                                      -6-
<PAGE>

valid and subsisting and in full force and effect, and is not subject to any
taxes or other fees except for annual filing and maintenance fees. To the best
of the Company's knowledge, each license which is material to the business of
the Company as conducted or the Proposed Business (i) is legally valid, binding
and enforceable and is in full force and effect, and (ii) immediately after the
Closing, will continue in full force and effect on identical terms and
conditions to those in effect prior to the Closing.

                  (c) The Company has not received any communication alleging
that the Company is interfering with, infringing, misappropriating or violating
or, by conducting Proposed Business, would materially interfere with, infringe,
misappropriate or violate any of the Intellectual Property of any other person
or entity (including any claim that the Company must license or refrain from
using any Intellectual Property rights of any third party).

                  (d) The Company is not aware that any of its employees is
obligated under any contract (including licenses, covenants or commitments of
any nature) or other agreement, or subject to any judgment, decree or order of
any court or administrative agency, that would interfere with the use of such
employee's best efforts to promote the interests of the Company or that would
conflict with the Proposed Business. Neither the execution nor delivery of this
Agreement, nor the carrying on of the Company's business by the employees of and
consultants to the Company, nor the conduct of the Proposed Business, will, to
the Company's knowledge, conflict with or result in a breach of the terms,
conditions or provisions of, or constitute a default under, any contract,
covenant or instrument under which any of such employees or consultants is now
obligated. The Company does not believe it is or will be necessary to utilize
any inventions of any of its employees (or people it currently intends to hire)
made prior to their employment by the Company, except those formally assigned or
transferred to the Company by such employees.

                  (e) Each of the Company's employees who, either alone or in
concert with others, (i) developed, invented, discovered, derived, programmed or
designed Intellectual Property or Inventions (as defined below), (ii) is
currently engaged in any research activities for the development, invention,
discovery, programming or design of Intellectual Property or Inventions, or
(iii) has knowledge of or access to information about Intellectual Property or
Inventions, has entered into a confidential information and inventions
assignment agreement in a form set forth in the Schedule of Exceptions.
"Inventions" means all inventions, developments and discoveries which during the
period of an employee's service to the Company he or she makes or conceives of,
either solely or jointly with others, that relate to any subject matter with
which his or her work for the Company may be concerned, or relate to or are
connected with the business, products, services or projects of the Company, or
relate

                                      -7-
<PAGE>

to the actual or demonstrably anticipated research or development of the
Company or involve the use of the Company's funds, time, material, facilities or
trade secret information, except as excluded pursuant to applicable law. The
Company is not aware that any of its employees is in violation thereof, and the
Company will use commercially reasonable efforts to prevent any such violation.

     2.10 Restructuring Agreements

     The execution and delivery by the Company of each of the Restructuring
Agreements, (as defined in Section 2.10 of the Schedule of Exceptions), and the
performance by the Company of its obligations thereunder have been duly
authorized by all necessary corporate action on the part of the Company. The
Restructuring Agreements constitute the valid and legally binding obligation of
the Company, enforceable in accordance with their respective terms, except (i)
as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors' rights
generally, and (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies.

     2.11 Compliance with Other Instruments

     The Company is not in violation or default of any provision of its Articles
of Incorporation or Bylaws, or in any material respect of any instrument,
judgment, order, writ, decree or contract to which it is a party or by which it
is bound, or, to the best of its knowledge, of any provision of any federal or
state statute, rule or regulation applicable to the Company. The execution,
delivery and performance of this Agreement, the Related Agreements and the
Restructuring Agreements, and the consummation of the transactions contemplated
hereby and thereby will not result in any such violation or be in conflict with
or constitute, with or without the passage of time and giving of notice, either
a default under any such provision, instrument, judgment, order, writ, decree or
contract or an event that results in the creation of any lien, charge or
encumbrance upon any assets of the Company or the suspension, revocation,
impairment, forfeiture, or nonrenewal of any material permit, license,
authorization, or approval applicable to the Company, its business or operations
or any of its assets or properties.

     2.12 Agreements; Action

          (a)  Except for agreements explicitly contemplated hereby, the
Related Agreements, and the Restructuring Agreements, there are no agreements or
understandings between the Company and any of its executive officers, directors,
affiliates, or any affiliate thereof.

                                      -8-
<PAGE>

          (b)  There are no agreements, understandings, instruments, or
contracts (other than the Restructuring Agreements and the licenses, options, or
other agreements relating to the Company's Intellectual Property which are
listed on Section 2.9(a) of the Schedule of Exceptions), nor any judgments,
orders, writs or decrees to which the Company is a party or by which it is
bound, (i) that may involve obligations (contingent or otherwise) of, or
payments to the Company in excess of, $250,000, or (ii) contain provisions which
materially restrict the development, manufacture or distribution of the
Company's products or services.

          (c)  The Company has not (i) declared or paid any dividends or
authorized or made any distribution upon or with respect to any class or series
of its capital stock, (ii) incurred any indebtedness for money borrowed or any
other liabilities individually in excess of $250,000 individually, (iii) made
any loans or advances to any person, other than ordinary advances for travel or
other business expenses, or (iv) sold, licensed (other than pursuant to the
licenses which are listed on Section 2.9(a) of the Disclosure Schedule),
exchanged or otherwise disposed of any of its assets or rights which are
material to the conduct of the Company's business as now conducted or the
Proposed Business.

          (d)  The Company is not a guarantor, indemnitor, surety or other
obligor of any indebtedness of any other Person.

          (e)  For the purposes of subsections (b) and (c) above, all
indebtedness, liabilities, agreements, understandings, instruments, contracts
and transactions involving the same person or entity (including persons or
entities the Company has reason to believe are affiliated therewith) shall be
aggregated for the purpose of meeting the individual minimum dollar amounts of
such subsections.

     2.13 Related-Party Transactions

     No executive officer or director of the Company or member of his or her
immediate family is indebted to the Company, nor is the Company indebted (or
committed to make loans or extend or guarantee credit) to any of them, except
for reimbursement of travel expenses, expenses for purchase of computers and
similar expenses incurred in the ordinary course at the request of the Company.
To the Company's knowledge, none of such persons has any direct or indirect
ownership interest in any firm or corporation with which the Company is
affiliated or with which the Company has a business relationship, or any firm or
corporation that competes with the Company, except that executive officers or
directors of the Company and members of their immediate families may own up to
5% of the capital stock of a publicly traded company with which the Company is
affiliated or has a business relationship. No member of the immediate family of
any executive officer or director

                                      -9-
<PAGE>

of the Company is directly or indirectly interested in any material contract
with the Company.

     2.14 Permits

     The Company has all franchises, permits, licenses, and any similar
authority necessary for the conduct of its business as now being conducted by
it, the lack of which could have a Material Adverse Effect. The Company is not
in default in any material respect under any of such franchises, permits,
licenses, or other similar authority.

     2.15 Environmental Laws

          (a)  To the best of the Company's knowledge, the Company is and has
been in compliance with all Environmental Laws and has obtained all necessary
Environmental Permits, all of which are in full force and effect except where
the failure to comply with such Environmental Laws or to obtain or maintain in
full force and effect such Environmental Permits would not have a Material
Adverse Effect.

          (b)  To the best of the Company's knowledge, except (i) as used in the
ordinary course of the Company's business and in compliance with Environmental
Laws, or (ii) as would reasonably not be expected to result in a Material
Adverse Effect, no Hazardous Material has been stored, accumulated, released,
spilled, discharged, dumped, disposed of or otherwise come to be located in, at,
beneath or near any of the Company's real or leased property or any properties
or assets formerly owned, operated or otherwise controlled by the Company.

          (c)  The Company has not received any oral or written notice, claim,
demand, suit or request for information from any governmental entity or person
with respect to any liability or alleged liability under any Environmental Law
that would be reasonably likely to result in a Material Adverse Effect.

          "Environmental Law" shall mean all applicable federal, State, county
or local statutes, laws, regulations, guidances, rules, ordinances, codes,
licenses, permits, judgments, writs, decrees, injunctions or orders of any
governmental entity having jurisdiction and enforcement authority over the
Property relating to environmental (air, water, groundwater, soil, noise and
odor) matters, including without limitation, the Clean Air Act, the Federal
Water pollution Control Act, the Resource Conservation and Recovery Act, as
amended by the Hazardous and Solid Waste Amendments of 1984, the Comprehensive
Environmental Response, Compensation and Liability Act, as amended by the
Superfund Amendments and Reauthorization Act of 1986, the Hazardous Materials
Transportation Act, the Toxic Substances

                                      -10-
<PAGE>

Control Act, the Washington Hazardous Waste Management Act and the Washington
Model Toxics Control Act.

          "Environmental Permits" shall mean all permits, licenses, approvals,
authorizations, consents or registrations required under applicable
Environmental Law.

          "Hazardous Material" shall mean any chemical, mixture, compound,
instrumentality, pollutant or other substance, including, without limitation
radioactive materials, regulated under any Environmental Law.

     2.16 Registration Rights and Voting Rights

     Except as provided in the Rights Agreement, the Company has not granted or
agreed to grant any registration rights, including piggyback rights, to any
person or entity. Except as contemplated in the Shareholders' Agreement, the
Company is not a party or subject to any agreement or understanding, and, to the
best of the Company's knowledge, there is no agreement or understanding between
any persons and/or entities, which affects or relates to the voting or giving of
written consents with respect to any security or by a director of the Company.

     2.17 Title to Property and Assets

     The Company has good and marketable title to its real properties and good
and sufficient title to its other assets, including all such properties and
assets reflected in its most recent audited balance sheet or purported to have
been acquired by the Company after the date of such balance sheet (except as
sold or otherwise disposed of in the ordinary course of business or in
accordance with the Restructuring Agreements), in each case free and clear of
all mortgages, liens, loans and encumbrances, except such encumbrances and liens
that arise in the ordinary course of business and do not materially impair the
Company's ownership or use of such property or assets. With respect to the
property and assets it leases, the Company is in compliance with such leases
and, to the best of its knowledge, holds a valid leasehold interest free of any
liens, claims or encumbrances.

     2.18 Employee Benefit Plans

          (a)  Section 2.18 of the Schedule of Exceptions sets forth: (i) all
"employee benefit plans", as defined in Section 3(3) of the U.S. Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), and all other
material employee benefit arrangements, maintained by the Company, or to which
the Company is a party or is required to contribute, or with respect to which
the Company has any material liability (the "Employee Benefit Plans").

                                      -11-
<PAGE>

          (b)  Except as set forth in Section 2.18 of the Schedule of
Exceptions, during the last six years, neither the Company nor any ERISA
Affiliate has sponsored, maintained or contributed to (or has been obligated to
contribute to) any "employee pension benefit plans", as defined in Section 3(2)
of ERISA, that is subject to Title IV of ERISA or Section 412 of the Code (each
such plan identified in the Schedule of Exceptions is referred to as a "Title IV
Plan"). To the Company's knowledge, (i) no Title IV Plan has an "accumulated
funding deficiency" as defined in Section 412 of the Code, whether or not
waived, and (ii) neither the Company nor any ERISA Affiliate has incurred any
material liability to the Pension Benefit Guaranty Corporation, which liability
has not been satisfied. For purposes of Section 2.18, "ERISA Affiliate" means
any trade or business that together with the Company is (or at the relevant time
was) treated as a single employer with the Company under Section 414(b), (c),
(m), or (o) of the Code.

          (c)  None of the Employee Benefit Plans is a multiemployer plan, as
defined in Section 3(37) of ERISA, and during the last six years neither the
Company nor any ERISA Affiliate has incurred any material liability due to its
withdrawal from, the termination or reorganization of a multiemployer plan,
which liability has not been satisfied.

          (d)  To the best of the Company's knowledge, there has been no
violation of ERISA or the Code or any other law relating to employment or
employees which could reasonably be expected to result in any material
liability, tax or penalty to the Company. Each Employee Benefit Plan that is
intended to qualify under Section 401 of the Code is the subject of an unrevoked
favorable determination letter from the Internal Revenue Service ("IRS") with
respect to such qualification, and, to the best of the Company's knowledge,
nothing has occurred with respect to the operation of any such Employee Benefit
Plan that could reasonably be expected to cause the loss of such plan's
qualification.

          (e)  There are no pending claims or lawsuits which have been asserted
or instituted against any of the Employee Benefit Plans, or against the Company
with respect to such plans, (other than routine benefit claims) which claims or
lawsuits if decided adversely to the Company would result in a material
liability to the Company, nor does the Company have knowledge of facts which
could reasonably be expected to form the basis for any such claim or lawsuit.

          (f)  Except as set forth in Section 2.18 of the Schedule of
Exceptions, neither the execution and delivery of this Agreement nor the
consummation of the transactions contemplated hereby will (i) result in a
material payment becoming due to any employee (current, former or retired) of
the Company, (ii) increase by a material amount any benefits otherwise payable
under any Employee Benefit Plan, or

                                      -12-
<PAGE>

(iii) result in any material payment becoming due to any employee that would be
nondeductible under Section 280G of the Code.

     2.19 Tax Returns, Payments and Elections

     The Company has filed all tax returns and reports (including information
returns and reports) as required by law. These returns and reports are true and
correct in all material respects. The Company has paid all taxes and other
assessments due, except those contested by it in good faith that are listed in
the Schedule of Exceptions. The Company has not elected pursuant to the Internal
Revenue Code of 1986, as amended (the "Code"), to be treated as a Subchapter S
corporation or a collapsible corporation pursuant to Section 1362(a) or Section
341(f) of the Code, nor has it made any other elections pursuant to the Code
(other than elections that relate solely to methods of accounting, depreciation
or amortization) that would have a Material Adverse Effect. The Company has
never had any tax deficiency proposed or assessed against it and has not
executed any waiver of any statute of limitations on the assessment or
collection of any tax or governmental charge. None of the Company's federal
income tax returns and none of its state income or franchise tax or sales or use
tax returns has ever been audited by governmental authorities. Since the date of
the Company's inception, the Company has not incurred any taxes, assessments or
governmental charges other than in the ordinary course of business and the
Company has made adequate provisions on its books of account for all taxes,
assessments and governmental charges with respect to its business, properties
and operations for such period. The Company has withheld or collected from each
payment made to each of its employees, the amount of all taxes (including, but
not limited to, federal income taxes, Federal Insurance Contribution Act taxes
and Federal Unemployment Tax Act taxes) required to be withheld or collected
therefrom, and has paid the same to the proper tax receiving officers or
authorized depositories.

     2.20 Employment and Labor Matters

          (a) The Company is in compliance in all material respects with all
laws regarding employment, wages, hours, equal opportunity, collective
bargaining and payment of social security and other taxes. The Company is not
engaged in any unfair labor practice or discriminatory employment practice and
no complaint of any such practice against the Company has been filed or, to the
best of the Company's knowledge, threatened to be filed with or by the National
Labor Relations Board, the Equal Employment Opportunity Commission or any other
administrative agency, federal or state, that regulates labor or employment
practices, nor is any grievance filed or, to the best of the Company's
knowledge, threatened to be filed, against the Company by any employee pursuant
to any collective bargaining or other employment agreement to which the Company
is a party or is bound. The Company

                                      -13-
<PAGE>

is in compliance in all material respects with all applicable foreign, federal,
state and local laws and regulations regarding occupational safety and health
standards, and has received no complaints from any foreign, federal, state or
local agency or regulatory body alleging violations of any such laws and
regulations.

                  (b)    The employment of each officer and employee of the
Company is terminable at the will of the Company. The Company has complied in
all material respects with all applicable state and federal equal employment
opportunity and other laws related to employment and there are no claims pending
or threatened against the Company by any current or former employees other than
routine claims for benefits under the Employee Benefit Plans.

         2.21     Brokers

         The Company has no contract, arrangement or understanding with any
broker, finder or similar agent with respect to the transactions contemplated by
this Agreement except that the Company will be responsible for the payment of
the commission due and owing Lehman Brothers ("Lehman") upon closing of such
transaction pursuant to arrangements between Novo Nordisk and Lehman.

         2.22     Absence of Certain Developments

         Since December 31, 1999, except as contemplated in the Restructuring
Agreements there has been no (i) change or event that would have a Material
Adverse Effect, (ii) material loss, destruction or damage to any property of the
Company, whether or not insured, (iii) acceleration or prepayment of any
indebtedness for borrowed money or the refunding of any such indebtedness, (iv)
labor trouble involving the Company or any material change in their personnel or
the terms and conditions of employment, (v) waiver of any valuable right, (vi)
loan or extension of credit to any officer or employee of the Company or (vii)
acquisition or disposition of any material assets (or any contract or
arrangement therefor), or any other material transaction by the Company or any
subsidiary otherwise than for fair value in the ordinary course of business.

         2.23     Illegal or Unauthorized Payments; Political Contributions

         Neither the Company nor, to the best of the Company's knowledge (after
reasonable inquiry of its officers and directors), any of the officers,
directors, employees, agents or other representatives of the Company or any
other business entity or enterprise with which the Company is or has been
affiliated or associated, has, directly or indirectly on behalf of the Company,
made or authorized any payment, contribution or gift of money, property, or
services, whether or not in contravention of applicable law, (i) as a kickback
or bribe to any person or (ii) to any political

                                      -14-
<PAGE>

organization, or the holder of or any aspirant to any elective or appointive
public office except for personal political contributions not involving the
direct or indirect use of funds of the Company.

         2.24     Insurance

         The Company and its properties are insured in such amounts, against
such losses and with such insurers as are prudent when considered in light of
the nature of the properties and businesses of the Company. Section 2.24 of the
Schedule of Exceptions sets forth a true and complete listing of the insurance
policies of the Company as in effect on the date hereof, including in each case
the applicable coverage limits, deductibles and the policy expiration dates. No
notice of any termination or threatened termination of any of such policies has
been received and such policies are in full force and effect.

         2.25     Full Disclosure

         The Company has fully provided each Investor with all the information
which such Investor has requested for deciding whether to purchase Series B
Shares. Neither this Agreement, the Rights Agreement, the Co-Sale Agreement, the
Shareholders' Agreement nor any other statements or certificates made or
delivered pursuant hereto, when taken together, contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements herein or therein not misleading in light of the circumstances under
which they were made.

         2.26     Minute Books

         The minute books of the Company contain a complete summary of all
meetings (or actions by consent in lieu of meetings) of directors, committees of
directors and shareholders since the time of incorporation and reflect all
transactions referred to in such minutes accurately in all material respects,
and complete copies have been provided to counsel for the Investors.

         2.27     Knowledge

         As used in this Section 2, the term "to the best of the Company's
knowledge" means, with respect to a representation or warranty so qualified, the
actual knowledge (after reasonable inquiry) of (i) the executive officers of the
Company and (ii) senior personnel of the Company who are regularly responsible
for the Company's functional or operational areas (such as, by way of example
only, finance, accounting, employee benefits or intellectual property legal
matters) which are relevant to the specific representation or warranty so
qualified.

                                      -15-
<PAGE>

2A.      Representations and Warranties of Novo Nordisk

         Novo Nordisk hereby represents and warrants that:

         2A.1     Restructuring Agreements

         The execution and delivery by Novo Nordisk of each of the Restructuring
Agreements, and the performance by Novo Nordisk of its obligations thereunder,
have been duly authorized by all necessary corporate action on the part of Novo
Nordisk. The Restructuring Agreements constitute the valid and legally binding
obligation of Novo Nordisk, enforceable in accordance with their respective
terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws of general application affecting
enforcement of creditors' rights generally, and (ii) as limited by laws relating
to the availability of specific performance, injunctive relief, or other
equitable remedies.

         2A.2     Intellectual Property

         Novo Nordisk has no knowledge of any information that, if known to the
Company, would cause any of the representations and warranties made by the
Company in Section 2.9 hereof not to be true and correct in any material
respect. For the purposes of this Section 2A.2, "knowledge" of Novo Nordisk
means the actual knowledge of Finn Benned Hansen and Pierre Honore acquired in
connection with the preparation and negotiation of the Restructuring Agreements.

3.       Representations and Warranties of the Investors

         Each Investor hereby represents and warrants, severally and not
jointly, that:

         3.1      Authorization

         Such Investor has full power and authority to enter into this Agreement
and the Related Agreements, and each such agreement constitutes its valid and
legally binding obligation, enforceable in accordance with its terms except (i)
as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors' rights
generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief, or other equitable remedies, and (iii) to the
extent the indemnification provisions contained in the Rights Agreement may be
limited by applicable federal or state securities laws.

                                      -16-
<PAGE>

         3.2      Purchase Entirely for Own Account

         This Agreement is made with such Investor in reliance upon such
Investor's representation to the Company, which by such Investor's execution of
this Agreement such Investor hereby confirms, that the Series B Shares to be
received by such Investor and the Conversion Shares (collectively, the
"Securities") will be acquired for investment for such Investor's own account,
not as a nominee or agent, and not with a view to the resale or distribution of
any part thereof, and that such Investor has no present intention of selling,
granting any participation in, or otherwise distributing the same. By executing
this Agreement, such Investor further represents that such Investor does not
have any contract, undertaking, agreement or arrangement with any person to
sell, transfer or grant participations to such person or to any third person,
with respect to any of the Securities.

         3.3      Disclosure of Information

         Such Investor has received all the information it considers necessary
or appropriate for deciding whether to purchase Series B Shares. Such Investor
further represents that it has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of
the Series B Shares and the business, properties, prospects and financial
condition of the Company. The foregoing, however, does not limit or modify the
representations and warranties of the Company in Section 2 of this Agreement or
the right of the Investors to rely thereon.

         3.4      Investment Experience

         Such Investor is an investor in securities of companies in the
development stage and acknowledges that it is able to fend for itself, can bear
the economic risk of its investment, including a total loss, and has such
knowledge and experience in financial or business matters that it is capable of
evaluating the merits and risks of the investment in the Series B Shares. If
other than an individual, such Investor also represents it has not been
organized for the purpose of acquiring the Series B Shares.

         3.5      Accredited Investor

         Such Investor is an "accredited investor" within the meaning of Rule
501 of Regulation D promulgated under the Securities Act.

         3.6      Restricted Securities

         Such Investor understands that the Securities have not been, and will
not be, registered under the Securities Act, by reason of a specific exemption
from the registration provisions of the Securities Act which depends upon, among
other things,

                                      -17-
<PAGE>

the bona fide nature of the investment intent and the accuracy of the Investor's
representations as expressed herein. The Investor understands that the
Securities are characterized as "restricted securities" under applicable U.S.
federal and state securities laws and that, pursuant to these laws, the Investor
must hold the Securities indefinitely unless subsequently registered with the
Securities and Exchange Commission and qualified by state authorities, or an
exemption from such registration and qualification requirements is available.
Other than as contained in the Rights Agreement, the Investor acknowledges that
the Company has no obligation to register or qualify the Securities for resale.
The Investor further acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period
for the Securities, and on requirements relating to the Company which are
outside of the Investor's control, and which the Company, other than as
contained in the Rights Agreement, is under no obligation and may not be able to
satisfy.

         3.7      Further Limitations on Disposition

         Without in any way limiting the representations set forth above, such
Investor further agrees not to make any disposition of all or any portion of the
Securities unless and until the transferee has agreed in writing for the benefit
of the Company to be bound by this Section 3 and the Related Agreements provided
and to the extent this Section and such agreement are then applicable, and:

                  (a)    There is then in effect a Registration Statement under
the Securities Act covering such proposed disposition and such disposition is
made in accordance with such Registration Statement; or

                  (b)    (i) Such Investor shall have notified the Company of
the proposed disposition and shall have furnished the Company with a detailed
statement of the circumstances surrounding the proposed disposition, and (ii) if
requested by the Company, such Investor shall have furnished the Company with an
opinion of counsel, reasonably satisfactory to the Company, that such
disposition will not require registration of such shares under the Securities
Act.

         3.8      Legends

         It is understood that the certificates evidencing the Securities may
bear one or all of the following legends:

         "THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR APPLICABLE STATE
SECURITIES LAWS, AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE
SOLD,

                                      -18-
<PAGE>

DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (A)
THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS COVERING ANY SUCH TRANSACTION INVOLVING SAID SECURITIES, (B)
THIS CORPORATION RECEIVES AN OPINION OF LEGAL COUNSEL FOR THE HOLDER OF THESE
SECURITIES SATISFACTORY TO THIS CORPORATION STATING THAT SUCH TRANSACTION IS
EXEMPT FROM REGISTRATION, OR (C) THIS CORPORATION OTHERWISE SATISFIES ITSELF
THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION."

         3.9      No Public Market

         Such Investor understands that no public market now exists for any
securities issued by the Company, and that the Company has made no assurances
that a public market for the securities will ever exist.

4.       Conditions of Investors' Obligations at Closing

         The obligations of each of the Investors to purchase Series B Shares
are subject to the fulfillment on the Closing of each of the following
conditions, the waiver of which shall not be effective against any Investor who
does not consent thereto:

         4.1      Representations and Warranties

         The representations and warranties of the Company contained in Section
2 shall be true on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of the date the Closing.

         4.2      Performance

         The Company shall have performed and complied with all agreements,
obligations and conditions contained in this Agreement that are required to be
performed or complied with by it on or before the Closing.

         4.3      Compliance Certificate

         The Chief Executive Officer and the Chief Financial Officer of the
Company shall have signed and delivered to the Investors at the Closing a
certificate stating that the conditions specified in Sections 4.1 and 4.2 have
been fulfilled.

                                      -19-
<PAGE>

     4.4  Restated Articles; Secretary's Certificate

     The Restated Articles shall have been duly filed with the Secretary of
State of the State of Washington and Company shall have delivered to the
Investors a copy of the Company's Restated Articles and Bylaws, as then in
effect, certified by the Company's Secretary as true and correct as of the
Closing.

     4.5  Qualifications

     All authorizations, approvals, or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are
required in connection with the lawful issuance and sale of the Securities
pursuant to this Agreement shall be duly obtained and effective as of the
Closing, including, without limitation, such filings and approvals as may be
required under the Hart-Scott Rodino Antitrust Improvement Act of 1976, as
amended.

     4.6  Rights Agreement

     The Company, Novo Nordisk Pharmaceuticals, Inc. ("NNPI") and each Investor
shall have entered into the Rights Agreement.

     4.7  Co-Sale Agreement

     The Company and each Investor shall have entered into the Co-Sale
Agreement.

     4.8  Shareholders' Agreement

     The Company, Novo Nordisk, NNPI and each of the Investors shall have
entered into the Shareholders' Agreement.

     4.9  Restructuring Agreements

     Each of the Restructuring Agreements shall be in full force and effect on
the date of the Closing.

     4.10 Executive Employment Agreement

     The Services Contract dated September 25, 1997 between Bruce L.A. Carter
("Carter") and the Company shall have been terminated and the Company and Carter
shall have entered into an employment agreement in a form reasonably acceptable
to WPEP.

                                      -20-
<PAGE>

     4.11 Opinion of Company Counsel

     The Investors shall have received an opinion of Perkins Coie LLP dated as
of the Closing, substantially in the form attached hereto as Exhibit G.
                                                             ---------

     4.12 Proceedings and Documents

     All corporate and other proceedings in connection with the transactions
contemplated at the Closing and all documents incident thereto shall be
reasonably satisfactory in form and substance to the Investors, and they shall
have received all such counterpart original and certified or other copies of
such documents as they many reasonably request.

5.   Conditions of the Company's Obligations at Closing

     The obligations of the Company to sell Series B Shares to the Investors are
subject to the fulfillment on the Closing of each of the following conditions:

     5.1  Representations and Warranties

     The representations and warranties of the Investors contained in Section 3
shall be true on and as of the Closing with the same effect as though such
representations and warranties had been made on and as of the date of the
Closing.

     5.2  Payment of Purchase Price

     The Investor shall have delivered the purchase price specified in Section
1.2.

     5.3  Qualifications

     All authorizations, approvals, or permits, if any, of any governmental
authority or regulatory body of the United States or of any state that are
required in connection with the lawful issuance and sale of the Securities
pursuant to this Agreement shall be duly obtained and effective as of the
Closing, including, without limitation, such filings and approvals as may be
required under the Hart-Scott Rodino Antitrust Improvement Act of 1976, as
amended.

     5.4  Rights Agreement

     The Company, NNPI and each Investor shall have entered into the Rights
Agreement.

                                      -21-
<PAGE>

     5.5  Co-Sale Agreement

     The Company and each Investor shall have entered into the Co-Sale
Agreement.

     5.6  Shareholders' Agreement

     The Company, NNPI and each Investor shall have entered into the
Shareholders' Agreement.

6.   Covenants Pending Closing

     (a)  Pending the Closing the Company will not, without WPEP's prior written
consent, take any action which would result in any of the representations or
warranties contained in this Agreement not being true at and as of the time
immediately after such action, or in any of the covenants contained in this
Agreement becoming incapable of performance. The Company will promptly advise
the Investors of any action or event of which it becomes aware which has the
effect of making incorrect any of such representations or warranties or which
has the effect of rendering any of such covenants incapable of performance.

     (b)  Each of the parties shall execute such documents and other papers and
take such further actions as may be reasonably required or desirable to carry
out the provisions hereof and the transactions contemplated hereby. Each such
party shall use its reasonable best efforts to fulfill or obtain the fulfillment
of the conditions to the Closing as promptly as practicable.

     (c)  Pending the closing, the Company and Novo Nordisk shall not, without
WPEP's prior written consent, amend, modify or terminate any of the
Restructuring Agreements.

     (d)  Pending the closing, the Company shall not, without WPEP's prior
written consent, enter into any agreement with Novo Nordisk (other than this
Agreement, the Related Agreements and the Restructuring Agreements) or with any
other party other than in the ordinary course of business.

7.   Miscellaneous

     7.1  Survival of Warranties

     The warranties, representations and covenants of the Company and Investors
contained in or made pursuant to this Agreement shall survive the execution and
delivery of this Agreement and the Closing hereunder and shall in no way be
affected

                                      -22-
<PAGE>

by any investigation of the subject matter thereof made by or on behalf of the
Investors or the Company.

     7.2  Successors and Assigns

     Except as otherwise provided herein, the terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties (including transferees of any Securities).
Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns
any rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

     7.3  Governing Law; Jurisdiction; Venue

     This Agreement shall be governed by and construed under the laws of the
State of Washington as applied to agreements among Washington residents entered
into and to be performed entirely within Washington, without giving effect to
principles of conflicts of laws. The parties irrevocably consent to the
jurisdiction and venue of the state and federal courts located in King County,
Washington in connection with any action relating to this Agreement.

     7.4  Counterparts

     This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and
the same instrument.

     7.5  Titles and Subtitles

     The titles and subtitles used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement.

     7.6  Notices

     Unless otherwise provided, any notice required or permitted under this
Agreement shall be given in writing and shall be deemed effectively given upon
personal delivery to the party to be notified, or upon confirmed facsimile
transmission, or one business day after deposit with a nationally recognized
overnight courier service, or upon deposit with the United States Post Office,
by registered or certified mail, postage prepaid and addressed to the party to
be notified (i) if to the Company or Novo Nordisk, at the address indicated for
such party on the signature page hereof, or (ii) if to an Investor, at the
address indicated for such party on Exhibit

                                      -23-
<PAGE>

A hereto, or at such other address as such party may designate by ten (10) days'
advance written notice to the other parties.

     7.7  Finder's Fee

     Except as described in Section 2.21 above, each party represents that it
neither is nor will be obligated for any finders' fee or commission in
connection with this transaction. Each Investor agrees to indemnify and to hold
harmless the Company from any liability for any commission or compensation in
the nature of a finders' fee (and the costs and expenses of defending against
such liability or asserted liability) for which such Investor or any of its
officers, partners, employees, or representatives is responsible. The Company
agrees to indemnify and hold harmless each Investor from any liability for any
commission or compensation in the nature of a finders' fee (and the costs and
expenses of defending against such liability or asserted liability) for which
the Company or any of its officers, employees or representatives is responsible.

     7.8  Fees and Expenses

     Each party to this Agreement shall pay all costs and expenses that it
incurs with respect to the negotiation, execution, delivery and performance of
this Agreement and the Related Agreements, except that the Company shall be
responsible for the payment of the State of Washington real estate excise tax
attributable to the transactions contemplated by this Agreement. If any action
at law or in equity is necessary to enforce or interpret the terms of this
Agreement or the Related Agreements, including an arbitration, the prevailing
party shall be entitled to reasonable attorney's fees, costs and necessary
disbursements in addition to any other relief to which such party may be
entitled.

     7.9  Amendments and Waivers

     Any term of this Agreement may be amended and the observance of any term of
this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), only with the written consent of the
Company and the holders of a majority of outstanding Series B Shares (or
Conversion Shares issued upon conversion thereof). Any amendment or waiver
effected in accordance with this paragraph shall be binding upon each holder of
any securities purchased under this Agreement at the time outstanding (including
securities into which such securities are convertible), each future holder of
all such securities, and the Company.

     7.10 Severability

     If one or more provisions of this Agreement are held to be unenforceable
under applicable law, such provision shall be excluded from this Agreement and
the balance

                                      -24-
<PAGE>

of the Agreement shall be interpreted as if such provision were so excluded and
shall be enforceable in accordance with its terms.

     7.11 Entire Agreement

     This Agreement (including the exhibits hereto) and the documents referred
to herein constitute the full and entire agreement among the parties and no
party shall be liable or bound to any other party in any manner by any
warranties, representations, or covenants, except as specifically set forth
herein or therein.

     7.12 Exculpation Among Investors

     Each Investor acknowledges that it is not relying upon any person, firm or
corporation (including without limitation, any other Investor), other than the
Company and its officers and directors (acting in their capacity as
representatives of the Company), in making its investment or decision to invest
in the Company. Each Investor agrees that neither any other Investor, nor the
respective controlling persons, officers, directors, partners, agents or
employees of any other Investor, shall be liable to such Investor for any losses
incurred by such Investor in connection with its investment in the Company.

                           [Signature Pages Follow]

                                      -25-
<PAGE>

     IN WITNESS WHEREOF, the parties have executed this Series B Preferred Stock
Purchase Agreement as of the date first above written.

                                         ZYMOGENETICS, INC.

                                         By: /s/ Bruce L.A. Carter
                                             --------------------
                                             Bruce L. A. Carter
                                             Its President and CEO

                                         Address: 1201 Eastlake Avenue East
                                                  Seattle, WA  98102
                                         Attn:    Bruce L.A. Carter

                                         Facsimile No.: (206) 442-6608

                                         NOVO NORDISK A/S

                                         By: /s/ Mads Ovlisen
                                             ----------------
                                             Mads Ovlisen
                                             Its President and CEO

                                         Address: Novo Alle
                                                  DK-2880
                                                  Bagsvaerd, Denmark
                                         Attn:    General Counsel
                                         Facsimile No.: 45 44 98 06 70

                                     -26-
<PAGE>

                                          INVESTORS:

                                          WARBURG, PINCUS EQUITY
                                          PARTNERS, L.P.

                                          By: Warburg, Pincus & Co.
                                              Its General Partner

                                              By: /s/Jonathan Leff
                                                  ----------------
                                                  Jonathan Leff, Partner

                                          WARBURG, PINCUS NETHERLANDS
                                          EQUITY PARTNERS I, C.V.

                                          By: Warburg, Pincus & Co.
                                              Its General Partner

                                              By: /s/Jonathan Leff
                                                  ----------------
                                                  Jonathan Leff, Partner

                                          WARBURG, PINCUS NETHERLANDS
                                          EQUITY PARTNERS II, C.V.

                                          By: Warburg, Pincus & Co.
                                              Its General Partner

                                              By: /s/Jonathan Leff
                                                  ----------------
                                                  Jonathan Leff, Partner

                                     -27-
<PAGE>

                                        WARBURG, PINCUS NETHERLANDS
                                        EQUITY PARTNERS III, C.V.

                                        By: Warburg, Pincus & Co.
                                            Its General Partner

                                            By: /s/Jonathan Leff
                                                ----------------
                                                Jonathan Leff, Partner

                                        APAX EXCELSIOR VI, L.P.

                                        By: Apax Excelsior VI Partners, L.P.
                                            Its General Partner

                                        By: Patricof & Co. Managers, Inc.
                                            Its General Partner

                                        By: /s/Lori Rafield
                                            ---------------
                                        Name: Lori Rafield, PhD
                                        Title: Vice President

                                        APAX EUROPE IV - A, L.P.
                                        (Delaware USA Limited Partnership)

                                        /s/Lori Rafield
                                        ---------------

                                        For and on behalf of Apax Europe IV GP
                                        Co. Limited acting in its capacity as
                                        managing general partner of Apax Europe
                                        IV GP, L.P. acting in its capacity as
                                        managing general partner of Apax Europe
                                        IV - A, L.P.

                                      -28-
<PAGE>

                                         APAX EUROPE IV - B, L.P.
                                         (English Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV - B, L.P.

                                         APAX EUROPE IV C, GMBH & CO.KG
                                         (German Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV C Gmbh & Co.KG

                                         APAX EUROPE IV - D, L.P.
                                         (English Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV - D, L.P.

                                      -29-
<PAGE>

                                         APAX EUROPE IV - E, L.P.
                                         (English Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV - E, L.P.

                                         APAX EUROPE IV - F, C.V.
                                         (Dutch Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity
                                         managing general partner of Apax Europe
                                         IV - F, C.V.

                                         APAX EUROPE IV - G, C.V.
                                         (Dutch Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV - G, C.V.

                                      -30-
<PAGE>

                                         APAX EUROPE IV - H, GmBH & CO., K.G.
                                         (German Limited Partnership)

                                         /s/Lori Rafield
                                         ---------------

                                         For and on behalf of Apax Europe IV GP
                                         Co. Limited acting in its capacity as
                                         managing general partner of Apax Europe
                                         IV GP, L.P. acting in its capacity as
                                         attorney of Apax Europe IV- H, GmbH &
                                         Co.K.G.

                                         FRAZIER HEALTHCARE III, L.P.

                                         By: FHM III, L.L.C.
                                             Its General Partner

                                         By: /s/Nader Naini
                                             --------------
                                         Name: Nader Naini
                                         Title: Managing Member

                                         FRAZIER AFFILIATES III, L.P.

                                         By: FHM III, L.L.C.
                                             Its General Partner

                                         By: /s/Nader Naini
                                             --------------
                                         Name: Nader Naini
                                         Title: Managing Member

                                         PATRICOF PRIVATE INVESTMENT CLUB
                                         III, L.P.

                                         By: Apax Excelsior VI Partners, L.P.
                                             Its General Partner

                                         By: Patricof & Co. Managers, Inc.
                                             Its General Partner

                                         By: /s/Lori Rafield
                                             ---------------
                                         Name: Lori Rafield, PhD
                                         Title: Vice President

                                      -31-
<PAGE>

                                      VERTICAL FUND ASSOCIATES, L.P.

                                      By: Vertical Group, L.P.
                                          Its General Partner

                                      By: /s/Stephen D. Baksa
                                          -------------------
                                      Name: Stephen D. Baksa
                                      Title: General Partner

                                      NOVO A/S

                                      By: /s/Kurt A. Nielsen
                                          ------------------
                                      Name: Kurt Anker Nielsen
                                      Title: Deputy CEO and Corporate Executive
                                             Vice President

                                      SILVER TIDE HOLDING S.A.

                                      By: /s/Ernesto Bertarelli
                                          ---------------------
                                      Name: Ernesto Bertarelli

                                      /s/George Rathmann
                                      ------------------
                                      Dr. George Rathmann

                                      /s/David Hirsh
                                      --------------
                                      Dr. David Hirsh

                                      /s/Daniel Rifkin
                                      ----------------
                                      Dr. Daniel Rifkin

                                      /s/Edward Skolnik
                                      -----------------
                                      Dr. Edward Skolnik

                                      -32-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]